432980.Kq
The company operates in the pharmaceuticals industry, generating revenue primarily through the development, production, and sale of pharmaceutical products.
Business. The company operates in the pharmaceuticals industry, generating revenue primarily through the development, production, and sale of pharmaceutical products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the pharmaceuticals industry, generating revenue primarily through the development, production, and sale of pharmaceutical products.
The company maintains a strong liquidity position, with cash and equivalents amounting to KRW 2,911,710,830, which is sufficient to cover its long-term debt of KRW 3,024,339,060. The liquidity FPT (free cash flow to total debt) is 0.40, indicating that the company generates enough free cash flow to cover its long-term debt obligations. The current ratio of 3.59 suggests a solid short-term liquidity buffer, with current assets significantly outpacing current liabilities.
Profitability metrics show a mixed picture. The company's return on equity (ROE) is 2.73%, which is below the industry median of 5.2%, while its return on assets (ROA) is 2.3%, also below the industry median of 4.8%. The net profit margin is 3.95%, which is slightly below the industry median of 4.1%. These figures suggest that the company is underperforming its peers in terms of asset and equity utilization.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic and regulatory risks. The absence of segment or geographic breakdown in the financial data limits the ability to assess the company's exposure to different markets.
The company's growth trajectory is modest. Revenue is projected to increase by 2.1% in the current fiscal year and by 1.8% in the next fiscal year. These growth rates are below the industry median of 3.5% for the current year and 3.2% for the next year. The company's capital expenditure is negative, indicating a reduction in investment, which may affect long-term growth potential.
The company faces moderate liquidity risk, with a liquidity risk score of medium. The key flag of net cash being negative after subtracting total debt indicates a potential liquidity constraint. The dilution risk is low, with no significant dilution sources identified in the risk assessment. The company has not issued additional shares recently, and there is no indication of dilution pressure in the near term.
Recent events include the filing of the latest financial report, which disclosed the company's financial position and performance. No significant earnings call transcripts or regulatory filings have been identified that would indicate material changes in the company's operations or strategy.
- The company has a strong liquidity position with a current ratio of 3.59 and sufficient cash to cover its long-term debt.
- Profitability metrics such as ROE and ROA are below industry medians, indicating underperformance in asset and equity utilization.
- The company's revenue is concentrated in a single segment, with no geographic diversification disclosed, increasing exposure to regional risks.
- Growth projections are modest, with revenue expected to increase by 2.1% in the current fiscal year and 1.8% in the next fiscal year.
- The company faces moderate liquidity risk but has low dilution risk, with no significant dilution sources identified.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- 432980.KQ Market data — financials · 2026-05-26